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Objectives. To study the applicability of a newly developed
echocardiographic scoring system in the assessment of carcinoid
valvular heart disease.
Background. We investigated prospectively the development,
progression and regression of carcinoid valvular heart disease in
patients with carcinoid syndrome by serial echocardiography,
correlating these features with urinary 5-HIAA levels and clinical
data collected during therapy with somatostatin analog.
Methods. Twenty-three patients with carcinoid syndrome un-
derwent serial echocardiographic examinations. An echocardio-
graphic carcinoid valvular heart disease (CVHD) % score was
determined from points assigned for tricuspid and pulmonary
valve structure and function.
Results. Fifteen patients had no CVHD at study entry (group 1),
while 8 patients had findings of CVHD (group 2). Five patients in
group 1 developed new CVHD (1B), while one demonstrated
progression of CVHD (2B). The remaining patients did not
develop (1A) or had no progression of CVHD (2B). Despite major
declines in 5-HIAA levels during therapy in most patients, CVHD
did not regress. There were significantly lower levels of median
baseline 5-HIAA (98.8 vs. 256 mg/24 h), posttreatment 5-HIAA
(50.3 vs. 324 mg/24 h) and posttreatment 5-HIAA time integral
(37.3 vs. 192 g/24 h* days) in group A vs. B (p < 0.05). However,
only posttreatment 5-HIAA levels independently predicted the
development or progression of CVHD by multiple step-wise re-
gression analysis (p < 0.005), with a threshold observed in the
100 mg/24 h range.
Conclusions. We designed a new echocardiographic scoring
system to evaluate CVHD. Correlating echocardiographic scores
with biochemical and clinical markers showed that only posttreat-
ment 5-HIAA levels independently predicted the development or
progression of CVHD. This study strengthens the association
between serotonin secretion and CVHD, as well as introducing a
new technique for serial follow-up of these patients.
(J Am Coll Cardiol 1998;32:1017–22)
©1998 by the American College of Cardiology
Carcinoid tumors are uncommon and arise from the entero-
chromaffin cells of the gastrointestinal tract and bronchi.
Carcinoid tumors may secrete large amounts of vasoactive
substances, including 5-hydroxytyptamine (serotonin) which is
subsequently metabolized to 5-HIAA by the endothelium of
the pulmonary and hepatic vasculature. The carcinoid syn-
drome occurs in less than 4% of patients with carcinoid tumor
(1,2) and is generally associated with hepatic metastases and
elevated urinary 5-HIAA levels. Clinically, carcinoid syndrome
is characterized by flushing, diarrhea, bronchoconstriction,
telangiectasias and right heart disease.
Heart disease characteristic of carcinoid has been previ-
ously reported in 19% to 66% of patients with carcinoid
syndrome (3–6). The characteristic cardiac lesion of carcinoid
heart disease consists of fibrous plaques covering normal
endothelium of the chambers and valves of the right heart (7).
Left heart involvement is uncommon and is generally associ-
ated with bronchial carcinoid or right-to-left intracardiac
shunting. Although the etiologic agent responsible for carci-
noid heart disease has not been identified, several studies have
implicated tumor secretory activity by demonstrating signifi-
cantly higher urinary 5-HIAA levels in patients with carcinoid
syndrome who have carcinoid heart disease (4,6).
Several analogs of the naturally occurring peptide soma-
tostatin have been shown to improve diarrhea and flushing in
patients with carcinoid syndrome while simultaneously lower-
ing urinary 5-HIAA levels. However, the impact of treatment
with these analogs on carcinoid tumor progression and cardiac
involvement has yet to be determined.
The present study was designed to investigate prospectively
the progression or regression of carcinoid heart disease in
patients with carcinoid syndrome using serial 2-dimensional
and Doppler echocardiograhpic studies employing a newly
developed scoring system. To establish the association of
carcinoid heart disease with urinary 5-HIAA levels, we corre-
lated our results with serial urinary 5-HIAA levels and clinical
data collected during therapy with somatostatin analog.
Methods
Study population. From November 1986 to August 1991,
23 patients with carcinoid syndrome were referred to Vander-
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bilt University for treatment with somatostatin analog. All 23
patients had histologically proven carcinoid, at least one of the
typical symptoms of carcinoid syndrome (flushing, diarrhea or
bronchoconstriction), and elevated urinary 5-HIAA levels. The
mean age at entry was 59 6 12 years (range 36 to 78 years).
There were 14 men and 9 women. The age at entry, duration
of carcinoid symptoms and extent of hepatic involvement with
tumor were noted at the time of entry into the study. The
extent of hepatic involvement with tumor was defined by
abdominal computer tomography (CT) scan as no involve-
ment, single hepatic metastasis or multiple hepatic metastases.
All patients were begun on somatostatin analog using a
protocol designed to determine the maximal tolerated dose.
Doses were increased on a monthly basis to the maximal
tolerated dose or a predetermined maximal dose (whichever
was less). Twenty patients received octreotide while three
received lantreotide.
Echocardiography. Two-dimensional (2D) echocardiogra-
phy, pulsed and continuous wave Doppler, and color flow
Doppler studies were performed using standard techniques on
each patient at entry into the study and serially approximately
every 6 months. All studies were performed on Hewlett-
Packard Sonos 500 or 1000 instruments and recorded on 1⁄2
in videotape. A total of 126 echocardiographic studies were
performed during the study.
To facilitate the detection of serial changes in carcinoid
heart disease, we devised a scoring system (Fig. 1) which
expressed the severity of carcinoid-induced valvular stenosis
and insufficiency in the right heart by combined two-
dimensional echocardiographic and Doppler criteria. This
Carcinoid Valvular Heart Disease (CVHD) score was deter-
mined by 1) tricuspid valve appearance, 2) tricuspid regurgi-
tation severity by either spectral pulsed wave or color Doppler
flow mapping; 3) pulmonary stenosis severity by spectral
pulsed or continuous wave Doppler, and 4) pulmonary insuf-
ficiency severity by color Doppler.
Tricuspid valve appearance was assigned 4 points and was
graded on a 1 to 4 point scale as normal, mildly, moderately, or
severely diseased. Grading was based upon qualitative assess-
ment of leaflet thickness, leaflet mobility and leaflet retraction
using all available echocardiographic views. Tricuspid valves
with normal appearance received only 1 point while severely
affected valves which were thickened, fixed and retracted
received 4 points.
Tricuspid regurgitation was also assigned 4 points in the
CVHD score and was graded based upon the color Doppler
appearance of the regurgitant jet (or pulsed wave Doppler
mapping in a few of the earliest studies) using a method similar
to that reported by Suzuki (8). The severity of TR was graded
from 1 to 4 by measuring the ratio of the color Doppler
regurgitant jet “mosaic” area to the right atrial RA area in the
apical 4 chamber view (TR/RA area ratio ,10% 5 1 point,
10–20% 5 2 points, 20–40% 5 3 points, and .40% 5 4
points). When pulsed wave Doppler mapping was used, the
severity of regurgitation was quantitated using the length of the
regurgitant jet (8).
Pulmonic valve stenosis (PS) was assigned 4 points as well
by measuring the peak Doppler velocity at the pulmonary
valve. One point was scored for peak velocities ,2 m/s
(gradient ,16 mm Hg), 2 points for 2–2.5 m/s (gradient
16–25 mm Hg). Higher severity scores were based on peak
Doppler velocities and the severity of TR (see Fig. 1).
Pulmonic valve insufficiency (PI) was assigned only 2 points
in the CVHD scoring system since no method for assessing its
severity is well validated and its clinical significance in carci-
noid heart disease is relatively small. PI was graded using a
color Doppler method analogous to the one used for aortic
insufficiency (9). Using the parasternal short axis view at the
aortic valve level, we determined the ratio of the width of the
regurgitant jet neck to the width of the pulmonary valve
annulus. One point was scored for ratios less than 0.33, and for
ratios greater than 0.33 2 points were scored.
Abbreviations and Acronyms
5-HIAA 5 5-hydroxyindoleacetic acid
CVHD 5 carcinoid valvular heart disease
CT 5 computed tomography
2D 5 two-dimensional
TR 5 tricuspid regurgitation
PI 5 pulmonic valve insufficiency
PS 5 pulmonic valve stenosis
RA 5 right atrium
Figure 1. Scoring system for carcinoid valvular heart disease
(CVHD% score). TR 5 tricuspid regurgitation, RA 5 right atrium,
PV 5 pulmonic valve, m/s 5 meters/second, and PI 5 pulmonic
insufficiency.
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The maximum number of possible points for any carcinoid
heart disease echo study was thus 14. However, since some
studies were inevitably too technically difficult to grade in one
or two categories, the CVHD score was reported as a percent-
age of the points possible on that study. The CVHD% score
thus equaled the total points scored divided by the points
possible on that study, expressed as a percentage. The maxi-
mum normal score equaled 4 of 14 possible points (CVHD%
score , 30), as in a patient with mild TR on color Doppler
study, a structurally normal tricuspid valve, and a normal
pulmonary valve.
All the echo studies were scored by a single observer
unaware of the patients’ previous echo scores or clinical and
laboratory data. Fifteen randomly selected echo studies were
rescored to determine the intraobserver variability. Based
upon this result, a significant change in score was defined as
greater than twice the standard deviation of the mean intraob-
server variability. Patients were then grouped based upon the
stability or progression of their carcinoid heart disease by
comparing their CVHD% scores from initial and final echo
studies.
Laboratory evaluation. Urinary 5-HIAA excretion was de-
termined by an assay utilizing fluorescence polarization immu-
noassay technology (TDx Assay, Abbott Laboratories) on
samples obtained before December 31, 1992 and by an assay
utilizing high performance liquid chromatography on samples
obtained after this date. Multiple 24-h urine collections were
obtained on each patient as they were admitted for serial
reevaluation of their response to treatment with somatostatin
analog at a minimum of 6 month intervals. Mean pre- and
posttreatment 24 h urinary 5-HIAA levels were determined for
each patient. Mean posttreatment 5-HIAA values were deter-
mined as the sum of all 24-h urine values, obtained after
therapy with somatostatin analog was initiated, divided by the
number of days sampled. Mean pre- and posttreatment 24-h
urinary 5-HIAA levels were expressed as mg/24 h. As a
measure of cumulative exposure to serotonin for each patient,
time-integrated urinary 5-HIAA levels were determined (Fig.
2) using the area under the curve of the multiple 24-h urinary
5-HIAA levels obtained over the period of follow up (result
expressed in grams/24 h 3 days).
Statistical methods. Many of the variables were not nor-
mally distributed after grouping, so the median and interquar-
tile ranges were used as measures of central tendency and
variation. The Mann-Whitney rank sum U test was used to
compare the data from groups of patients who were either
stable or progressed with respect to echocardiographic evi-
dence of carcinoid valvular heart disease. Univariate and
multiple step-wise regression analyses were used to determine
the clinical and laboratory predictors of echocardiographic
progression of carcinoid valvular heart disease. Statistical
significance was determined at the p , 0.05 level.
Results
Echocardiography. Typical right heart carcinoid valvular
abnormalities were observed in 8 patients (35%) on their
initial 2D echocardiogram and Doppler study, while the re-
maining 15 patients showed no evidence of carcinoid heart
disease. Those patients without carcinoid heart disease on the
initial 2D echo were placed in group 1; those with carcinoid
heart disease were placed in group 2. Since the intraobserver
reproducibility study of 15 patients revealed a mean absolute
difference in CVHD% score of 3.8 with a standard deviation of
4.7, a .10 point change in score was judged to be significant.
As shown in Table 1, patients were thus further classified into
those who demonstrated no echocardiographic progression or
development of carcinoid heart disease (subgroup A) and
those whose carcinoid heart disease progressed or developed
(subgroup B).
Of the 15 patients who entered the study without evidence
of carcinoid heart disease (group 1, median CVHD% score
29), 10 patients remained unaffected (group 1A, median
absolute increase in CVHD% score of 0), while the other 5
developed new echocardiographic changes typical of carcinoid
heart disease (group 1B, median absolute increase in CVHD%
score of 28). Of the 8 patients demonstrating echocardio-
graphic evidence of carcinoid heart disease at entry (group 2,
median CVHD% score of 70), 7 patients remained stable
(group 2A, median absolute increase in CVHD% score of 4)
while 1 patient demonstrated progressive carcinoid heart dis-
ease (group 2B, median increase in CVHD% score of 15).
Echocardiographic regression of carcinoid heart disease was
not observed in any patient despite treatment with somatosta-
tin analog. That is, an improvement in CVHD% score of 10 or
Figure 2. Time-integrated urinary 5-HIAA for one patient. Shaded
area represents the integral value.
Table 1. Baseline *CVHD % Score and Score Change
With Follow-Up
Group N
Baseline CVHD
% Score
median (range)
CVHD %
Score Change
median (range)
1A 10 29 (28–30) 0 (0–1)
1B 5 (Group 1) 28 (28–34)
2A 7 70 (54–75) 4 (0–4)
2B 1 (Group 2) 15
*CVHD 5 carcinoid heart disease.
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more was never sustained on more than 2 serial echocardio-
grams.
Clinical data. Comparison of clinical variables at presen-
tation in patients without echocardiographic evidence of car-
cinoid heart disease (group 1) and those with carcinoid heart
disease (group 2) is summarized in Table 2. All but 2 patients
showed either single or multiple hepatic metastases on abdom-
inal CT scan. Although patients with carcinoid heart disease at
entry tended to have carcinoid symptoms of greater duration,
higher baseline urinary 5-HIAA levels and multiple metasta-
ses, these differences did not reach statistical significance.
Clinical variables from all patients who showed no signifi-
cant echocardiographic evidence of progression/development
of carcinoid valvular heart disease (group A) were then com-
pared with those who demonstrated progression/development
(group B). As shown in Figure 3, there were statistically
significant differences in baseline urinary 5-HIAA levels (98.8
[59–186] vs. 256 [145–356] mg/24 h), posttreatment urinary
5-HIAA levels (50.3 [27–90] vs. 324 [103–458] mg/24 h), and
posttreatment urinary 5-HIAA integral (37.3 [21–79.2] vs. 192
[59–703] g/24 h 3 days) (median [range]) (p , 0.05). There
was no significant difference between these groups in the
duration of carcinoid symptoms prior to entry, duration of
treatment with somatostatin analogue, or percent change in
urinary 5-HIAA levels (Table 3).
Table 4 compares clinical variables from the subgroup of
patients who entered the study without echocardiographic
evidence of carcinoid heart disease and remained stable (group
1A) with those who developed new evidence of disease (group
1B). Patients from group 1B had significantly higher baseline
urinary 5-HIAA levels (319 [193–356] vs. 77 [42–112] mg/24 h),
post-treatment urinary 5-HIAA levels (442 [207–458] vs. 57.8
[20–90] mg/24 h), and posttreatment urinary 5-HIAA integrals
(238 [59–703] vs. 34.2 [12–79] g/24 h* days) (median [range])
(p , 0.05) (Fig. 4). No statistically significant differences were
shown in the duration of carcinoid symptoms prior to entry,
percent change in urinary 5-HIAA levels, or duration of
therapy with somatostatin analogue.
As shown in Table 5, three clinical variables were found to
predict carcinoid valvular heart disease progression by univar-
iate analysis. These were the posttreatment urinary 5-HIAA
levels, the baseline urinary 5-HIAA levels and the 5-HIAA
integral (p , 0.05). However, multiple step-wise regression
analysis showed that only the posttreatment urinary 5-HIAA
levels independently predicted the progression of carcinoid
valvular heart disease (p , 0.005).
During the 6-year-study period, the mortality rates were
3/10 (30%) for group 1A, 3/5 (60%) for group 1B, 1/7 (14%)
for group 2A and 1/1 (100%) for group 2B.
Discussion
This prospective study used a new echocardiographic scor-
ing system to document progression or regression of carcinoid
valvular heart disease in serial studies. This CVHD scoring
system is based upon the structure of the right heart valves as
shown by 2D echocardiography, and upon their function as
shown by Doppler echocardiography. In this study of patients
with histologically proven metastatic carcinoid tumor, the 35%
incidence of cardiac involvement on the initial echocardiogram
is similar to that of previous studies (4–6). Although patients
with cardiac involvement on their initial echocardiogram
tended to have had symptoms of longer duration, higher
baseline urinary 5-HIAA levels, and more frequent multiple
hepatic metastases, none of these differences reached statisti-
cal significance. Pellikka et al. in an echocardiograhic study of
132 patients with carcinoid syndrome noted no difference in
patients with carcinoid heart disease and those without carci-
noid heart disease with regard to symptom duration, time from
diagnosis or location of the primary tumor (10). However, they
did note higher mean pretreatment 5-HIAA levels in patients
with carcinoid heart disease than in those without carcinoid
heart disease. The ranges of values were quite broad with
moderate overlap between the 2 groups.
In this study, the development and progression of carcinoid
heart disease during treatment with somatostatin analog were
clearly linked to elevated urinary 5-HIAA levels. The 5 pa-
tients who developed carcinoid heart disease de novo during
the study had significantly higher median urinary 5-HIAA
levels and higher urinary 5-HIAA integrals than those who
remained free of carcinoid heart disease. None of the other
Figure 3. Comparison of urinary 5-HIAA levels in patients with stable
(group A) and progressive (group B) carcinoid heart disease. Bars
represent median values with ranges noted by hash marks.
Table 2. Clinical Variables for Patients With and Without
Echocardiographic Evidence for Carcinoid Heart Disease
Group 1
(n 5 15)
median
(range)
Group 2
(n 5 8)
median
(range)
Baseline echocardiogram score 29% (28–30) 70% (54–75)
Symptom duration (mos) 17 (4–25) 43 (12–103) *NS
Baseline **5-HIAA (mg/24 h) 106.7 (59–193) 144.6 (99–358) NS
Multiple hepatic metastases 63% 83% NS
*NS 5 nonsignificant, **5-HIAA 5 5-hydroxyindoleacetic acid.
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clinical variables, including duration of therapy, differed sig-
nificantly between those who suffered progressive carcinoid
heart disease and those who did not.
Our scoring system did not include mitral CVHD, which is
only seen in 7% of cases (10). Only 1 patient in this study
exhibited mitral valve disease with thickening and decreased
excursion of the mitral valve leaflets (4%). This patient had a
bronchial carcinoid tumor and simultaneously showed progres-
sion of pre-existing right heart involvement.
Stabilization or regression. Interestingly, regression of car-
cinoid disease (defined as a significant decrease in CVHD%
score of .10 points on serial echocardiography) was not
observed during treatment with somatostatin analog. Although
the median posttreatment urinary 5-HIAA level was reduced
to less than 50% of pretreatment level in 6 patients who
entered the study with carcinoid heart disease, CVHD% score
by echocardiography did not change significantly in these
patients. There was a trend toward lower posttherapy 5-HIAA
levels in the group with stable carcinoid heart disease when
compared with the group with progressive or new carcinoid
heart disease. Failure of this trend to reach statistical signifi-
cance may be due to the small sample size as well as significant
overlap of the ranges for percent change in 5-HIAA levels.
Nevertheless, if more patients with pre-existing carcinoid heart
disease can be followed after major reduction in urinary
5-HIAA levels, effective therapy may be shown to stabilize or
even regress carcinoid disease.
Although it has been hypothesized that exposure of the
endocardium to elevated levels of serotonin (4,6) or other
secreted tachykinins such as neuropeptide K or substance P(4)
might lead to fibroblast proliferation, the exact etiology of the
fibrous plaques is obscure. Of the three clinical variables
identified in the univariate analysis as predictors of progression
of carcinoid heart disease (baseline urinary 5-HIAA levels,
posttreatment urinary 5-HIAA levels, and the posttreatment
urinary 5-HIAA time integral), only the posttreatment urinary
5-HIAA level was significant by multiple step-wise regression
analysis. Failure of the posttreatment urinary 5-HIAA time
integral to independently predict progression of carcinoid
heart disease suggests that the absolute elevation in serotonin
secretion is more important than cumulative exposure to
serotonin. That is, there may be a threshold value of serotonin
secretion above which fibroblast proliferation is activated. As
shown in Figures 3 and 4, the threshold for urinary 5-HIAA
values during therapy appears to be in the 100 mg/24 h range.
Morbidity and Mortality. Since right heart failure contrib-
utes significantly to the morbidity and mortality associated with
malignant carcinoid tumors, predictors of carcinoid heart
disease development may be useful. Indeed, mortality in the
patients who developed new (group 1B) or progressive (group
2B) CVHD was more than twice that of patients with no
(group 1A) or stable (group 2A) carcinoid heart disease. Since
persistent elevations in urinary 5-HIAA levels despite therapy
(.100 mg/24 h) were independently associated with develop-
Table 3. Symptom Duration and Urinary *5-HIAA Levels in Patients With Stable and Progressive CVHD
**CVHD Stable/Absent
median (range)
CVHD Progression/Development
median (range)
Symptom duration (mos) 9 (3–38) 22 (18–27) #NS
Baseline 5-HIAA (mg/24 h) 98.8 (59–186) 256 (145–356) p , 0.05
Posttreatment 5-HIAA (mg/24 h) 50.3 (27–90) 324 (103–458) p , 0.005
5-HIAA change 243% (271 to 22%) 22% (229 to 129%) NS
Posttreatment 5-HIAA integral
(g/24h* Days)
37.3 (21–79.2) 192 (59–703) p , 0.05
Duration of therapy with
somatostatin analog (days)
860 (553–1484) 1216 (1059–1416) NS
*5-HIAA 5 5-hydroxyindoleacetic acid, **CVHD 5 carcinoid valvular heart disease, #NS 5 nonsignificant.
Table 4. Symptom Duration and Urinary *5-HIAA Levels in Patients Without Carcinoid Heart
Disease at Baseline Who Either Remained Without (1A) or Developed Carcinoid Heart Disease (1B)
During Therapy
Group 1A
(n 5 10)
Median (range)
Group 1B
(n 5 5)
Median (range)
Symptom duration (mos) 9 (3–17) 18 (18–25) **NS
Baseline 5-HIAA (mg/24 h) 77 (42–112) 319 (193–356) p , 0.05
Posttreatment 5-HIAA (mg/24 h) 57.8 (20–90) 442 (207–458) p , 0.005
5-HIAA change 215% (224 to 19%) 7% (211 to 129%) NS
Posttreatment 5-HIAA integral
(g/24 h 3 Days)
34.2 (12–79) 238 (59–703) p , 0.05
Duration of therapy with
somatostatin analog (days)
648 (359–1221) 1152 (1059–1279) NS
*5-HIAA 5 5-hydroxyindoleacetic acid, **NS 5 nonsignificant.
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ment or progression of carcinoid heart disease, aggressive
attempts to reduce 5-HIAA levels below this threshold appear
justified.
The CVHD% score provides a compilation of right heart
pathology which can be used to monitor CVHD development
and progression quantitatively. A larger study is needed to
determine whether aggressive reduction of urinary 5-HIAA
levels will reliably prevent or halt the progression of cardiac
involvement. It has been suggested that a lower 5-HIAA level
prior to valvular surgery correlates with improved postopera-
tive survival (11). Surgical intervention with valvuloplasty or
valve replacement remains the best means of improving right
heart valvular function since regression of carcinoid valvular
heart disease was not observed in this study during treatment
with somatostatin analog.
Limitations and conclusions. One limiting feature of this
study is the relatively small number of patients following
during therapy for this relatively uncommon condition, meta-
static carcinoid tumor. Although the differences in 5-HIAA
levels were statistically significant, we still can only speculate
on the role serotonin plays in carcinoid heart disease. Never-
theless, this prospective study demonstrated the usefulness of a
new echocardiographicscoring system to evaluate the presence
and severity of carcinoid heart disease by serial 2D and
Doppler echocardiography. In those patients demonstrating
echocardiographic progression of carcinoid heart disease, uri-
nary 5-HIAA levels were significantly higher both before and
during therapy with somatostatin analog. This study strength-
ens the association between serotonin secretion and carcinoid
heart disease, and it also demonstrates the application of serial
echocardiography in patients with malignant carcinoid tumors.
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Figure 4. Urinary 5-HIAA levels in patient without carcinoid heart
disease at baseline who remained stable (group 1A) or developed
carcinoid heart disease during follow-up (group 1B). Bars represent
median values with ranges noted by hash marks.
Table 5. Predictors of Carcinoid Heart Disease Progression
**Mean post RX 5-HIAA levels p , 0.05
Baseline 5-HIAA levels p , 0.05
5-HIAA-time integral p , 0.05
% change in 5-HIAA NS
Age NS
Sex NS
Symptom duration NS
Baseline echo score NS
Multiple hepatic metastases NS
Study duration NS
**Only significant variable by multiple stepwise regression (p , 0.005).
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